Pulmonary infections in the returning traveler

PURPOSE OF REVIEW

The recent COVID-19 pandemic has shaped the epidemiology of other infectious diseases globally. International tourist arrivals are increasing and recovering to prepandemic levels. This review focuses on respiratory infections in travelers, highlighting the characteristics of the main imported viral, bacterial, fungal, and parasitic infections with pulmonary involvement.

RECENT FINDINGS

A recent systematic review estimated a prevalence of respiratory symptoms in travelers of around 35%, increasing to nearly 65% in the context of mass gatherings. Common viral and bacterial pathogens account for the majority of respiratory infections with an identified cause; however, recent data focus on the need for surveillance of emerging infections such as MERS-CoV, henipaviruses and multidrug resistant bacteria, which may be spread through travel. Fungal and parasitic respiratory infections are less common, and acquisition is usually associated with specific risk factors or exposure in endemic areas. Special risk groups, such as immunocompromised travelers, may be particularly vulnerable, presenting with severe disease or reactivation of latent infections.

SUMMARY

The next significant international epidemic could involve another new infectious agent causing respiratory disease and spreading via mobile populations. Official protocols should be adhered to, and public health interventions implemented for effective control. Continued and globally coordinated investments in research for new vaccines, therapeutic agents, disease modeling, and digital tracking strategies are essential.

Bilateral pulmonary infiltrates in a traveller from Saudi Arabia with probable electronic cigarette or vaping associated lung injury (EVALI)

A Saudi traveller presented with fever and pulmonary infiltrates. Principal causes of infectious pneumonia were ruled out (including MERS-coronavirus) and a diagnosis of probable drug-induced pneumonitis due to vaping/electronic cigarettes was established. Professionals should be aware of international epidemiological alerts but also consider non-infectious causes of pneumonia in travellers.

Chagas Disease in Europe

Chagas disease is currently present in many non-endemic countries and remains a neglected tropical disease globally. A review of the literature identified significant gaps and scarcity of updated information from European countries, with most studies reporting data from Spain and Italy. The index of underdiagnosis may be as high as 70%, affecting mainly females of child-bearing age. Standardized screening of fertile, non-pregnant, women from endemic countries and subsequent treatment is considered an essential strategy to control transmission and prevent new cases, yet no uniform legislation for screening risk groups exists. There is heterogeneity in Europe in terms of preventive strategies to avoid transfusion-related transmission of Chagas disease, not necessarily in line with the European directives, with some countries conducting systematic screening for T. cruzi infection in blood donors, whilst others rely on pre-transfusion questionnaires. The growing burden of the infection in resource-rich areas may provide an opportunity for progress in certain aspects of control and prevention. Options for improving screening strategies, management and linkage to care are reviewed.

Haemoglobinopathies in mobile populations from sub-Saharan Africa

A frequency of HbS or haemoglobin C trait of 15% was found in a cohort of recently arrived, mainly asymptomatic, young sub-Saharan Africans, using a simple point-of-care screening test. Screening allows early diagnosis of haemoglobinopathies in vulnerable populations facilitating linkage to care, genetic counselling and implementation of treatment and prevention strategies.